
    
      This is a Phase 1b, single-center, dose-escalating study to evaluate the safety,
      tolerability, and pharmacodynamic effect of RBT-1 in healthy volunteers and in subjects with
      stage 3b-4 CKD. The following biomarkers will be used as surrogate measures of protective
      activity: Haptoglobin, Ferritin, Bilirubin, Hemopexin, IL-10, and Heme Oxygenase-1.
      Additionally, the P21 biomarker will be monitored at various points of the study.
    
  